IBEX 35
11.034,50 -84,40 (-0,76%) Euro Stoxx 50
4.915,50 -20,47 (-0,41%) Dólar/Euro
1,0687 -0,0029 (-0,27%) Petróleo Brent
84,54 -0,47 (-0,55%) Oro
2.309,90 -20,90 (-0,90%) Bitcoin EUR
57.814,91 +114,96 (+0,20%)
Mind Medicine (MindMed) Inc. (MNMD)
Mind Medicine (MindMed) Inc.
One World Trade Center
Suite 8500
New York, NY 10007
United States
212-220-6633
https://www.mindmed.co
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 57
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Robert Barrow | CEO & Director | 931,13k | N/A | 1989 |
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer | 658,52k | N/A | 1980 |
| Dr. Miriam Halperin Wernli M.B.A., Ph.D. | Executive President | 552,46k | N/A | 1953 |
| Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor | 314,82k | N/A | 1957 |
| Mr. Leonard Latchman | Co-founder | N/A | N/A | N/A |
| Ms. Carrie F. Liao CPA, CGMA | VP & Chief Accounting Officer | N/A | N/A | 1966 |
| Mr. Mark R. Sullivan J.D. | Chief Legal Officer & Corporate Secretary | N/A | N/A | 1971 |
| Dr. Francois P. Lilienthal M.B.A., M.D. | Chief Commercial Officer | N/A | N/A | N/A |
Descripción
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Gobierno corporativo
El ISS Governance QualityScore de Mind Medicine (MindMed) Inc., a día 1 de junio de 2024, es 8. Las puntuaciones base son Auditoría: 8; Tablero: 4; Derechos de los accionistas: 3; Compensación: 10.
